Posted by Michael Wonder on 13 Jul 2022
Accelerating pooled licensing of medicines to enhance global production and equitable access
8 July 2022 - From October to November, 2021, the pharmaceutical firms Merck and Pfizer licensed their new COVID-19 oral antiviral medications to the Medicines Patent Pool.
In both cases, the drugs were licensed quickly, before they were launched, and the Medicines Patent Pool then reached agreements with pharmaceutical firms across the globe (27 firms for Merck's molnupiravir and 36 firms for Pfizer's nirmatrelvir) to provide generic versions of these to roughly 100 low-income and middle-income countries.
